Harmony Biosciences Reports Q3 2026 Revenue of $269 Million
Harmony reported Q3 net revenue of $269 million and EPS of $0.81, below analyst expectations of $1.09. It reiterated 2026 revenue guidance of $1.0 billion to $1.04 billion.
Story updates
Harmony Biosciences reported third-quarter 2026 net revenue of $269 million, driven by 400 net patient additions for its flagship product, WAKIX. The company reported an EPS of $0.81, which fell below analyst expectations of $1.09. Despite the earnings miss, Harmony reiterated its full-year 2026 net revenue guidance of $1.0 billion to $1.04 billion. The company also provided updates on its clinical pipeline, noting that preliminary data from its multiple-ascending dose study for BP-205 showed a favorable safety and pharmacokinetic profile.
Additionally, Harmony confirmed that Peter Anastasiou will succeed Dr. Jeffrey Dayno as President and CEO, effective January 1, 2027.